Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Deoxycholic Acid

FDA-approved product (solution, subcutaneous), marketed as Deoxycholic Acid, Kybella.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Deoxycholic Acid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Deoxycholic Acid. Its therapeutic class is shown instead.

WHO therapeutic group
Other dermatologicals
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli19.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Deoxycholic Acid in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Deoxycholic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

    NCT07378761 · start 2026-06-25

    Registered record
    Registry ID
    NCT07378761
    Conditions
    Immune-Mediated Cholestasis
    Interventions
    UDCA (Ursodeoxycholic acid); Corticosteroids (Reference Treatment)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-25
    Completion
    2028-12
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune-Mediated Cholestasis
    InterventionUDCA (Ursodeoxycholic acid); Corticosteroids (Reference Treatment)
    PhasePhase 2
    Registry statusRecruiting

  • Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors

    NCT07672860 · start 2026-06-01

    Registered record
    Registry ID
    NCT07672860
    Conditions
    Kidney Cancer
    Interventions
    UDCA (Ursodeoxycholic acid); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-01
    Completion
    2027-12
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    InterventionUDCA (Ursodeoxycholic acid); Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

    NCT06884748 · start 2026-05-01

    Registered record
    Registry ID
    NCT06884748
    Conditions
    Clostridioides Difficile Infection
    Interventions
    Ursodiol 500 MG
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2028-05-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClostridioides Difficile Infection
    InterventionUrsodiol 500 MG
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • UDCA to Prevent Post-TIPS Hepatic Encephalopathy

    NCT07273734 · start 2026-01-01

    Registered record
    Registry ID
    NCT07273734
    Conditions
    Hepatic Encephalopathy (HE); TIPS
    Interventions
    Ursodeoxycholic Acid (UDCA); Lactulose
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-01-01
    Completion
    2027-12-31
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy (HE); TIPS
    InterventionUrsodeoxycholic Acid (UDCA); Lactulose
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

    NCT07068191 · start 2025-06-19

    Registered record
    Registry ID
    NCT07068191
    Conditions
    Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Hepatomegaly; Nonalcoholic Fatty Liver (NAFL); Nonalcoholic Fatty Liver Disease (NAFLD); Fatty Liver; Fatty Liver, Alcoholic; Fatty Liver, Nonalcoholic; Fatty Liver Disease
    Interventions
    Dietary supplement "Gepaktiv"; UDCA (Ursodeoxycholic acid); Ademetionine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-06-19
    Completion
    2025-08
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Hepatomegaly; Nonalcoholic Fatty Liver (NAFL); Nonalcoholic Fatty Liver Disease (NAFLD) +4 more
    InterventionDietary supplement "Gepaktiv"; UDCA (Ursodeoxycholic acid); Ademetionine
    PhaseNot applicable
    Registry statusRecruiting

  • Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis

    NCT06926569 · start 2025-05-01

    Registered record
    Registry ID
    NCT06926569
    Conditions
    HIV/AIDS-associated Talaromycosis
    Interventions
    Amphotericin B; AmBisome
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2026-05-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS-associated Talaromycosis
    InterventionAmphotericin B; AmBisome
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

    NCT06783621 · start 2025-01-16

    Registered record
    Registry ID
    NCT06783621
    Conditions
    Facial Contouring
    Interventions
    OnabotulinumtoxinA; JUVÉDERM; CoolSculpting Elite System; SkinMedica Products; KYBELLA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-01-16
    Completion
    2026-03-20
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFacial Contouring
    InterventionOnabotulinumtoxinA; JUVÉDERM; CoolSculpting Elite System; SkinMedica Products +1 more
    PhasePhase 4
    Registry statusCompleted

  • Efficacy, Satisfaction, and Safety of the Mesolipo® Protocol for the Treatment of Localized Adiposity

    NCT07743788 · start 2025-01-01

    Registered record
    Registry ID
    NCT07743788
    Conditions
    Localized Adiposity
    Interventions
    Mesolipo®; Pentoxifylline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-01-01
    Completion
    2025-06-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocalized Adiposity
    InterventionMesolipo®; Pentoxifylline
    PhaseNot applicable
    Registry statusCompleted

  • A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

    NCT06756490 · start 2024-12-26

    Registered record
    Registry ID
    NCT06756490
    Conditions
    Moderate or Severe Submental Fullness
    Interventions
    HY-2003 (10 mg/ml), BELKYRA and placebo; HY-2003 (5 mg/ml) and placebo; HY-2003 (5 mg/ml) and placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-12-26
    Completion
    2027-05-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate or Severe Submental Fullness
    InterventionHY-2003 (10 mg/ml), BELKYRA and placebo; HY-2003 (5 mg/ml) and placebo; HY-2003 (5 mg/ml) and placebo
    PhasePhase 1
    Registry statusRecruiting

  • Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance

    NCT06684106 · start 2024-11-25

    Registered record
    Registry ID
    NCT06684106
    Conditions
    Hyperlipidemia; Ursodeoxycholic Acid; Statin Therapy; Glucose Intolerance
    Interventions
    Ursodeoxycholic acid (UDCA) 500 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-11-25
    Completion
    2027-06-01
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia; Ursodeoxycholic Acid; Statin Therapy; Glucose Intolerance
    InterventionUrsodeoxycholic acid (UDCA) 500 mg; Placebo
    PhaseNot applicable
    Registry statusRecruiting

  • A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

    NCT06591455 · start 2024-09-14

    Registered record
    Registry ID
    NCT06591455
    Conditions
    Primary Biliary Cholangitis (PBC)
    Interventions
    Fenofibrate; UDCA (Ursodeoxycholic acid)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-09-14
    Completion
    2025-08-18
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cholangitis (PBC)
    InterventionFenofibrate; UDCA (Ursodeoxycholic acid)
    PhaseEarly phase 1
    Registry statusCompleted

  • A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis

    NCT06447402 · start 2024-06-03

    Registered record
    Registry ID
    NCT06447402
    Conditions
    Chronic Pulmonary Aspergillosis; CPA; Aspergilloma
    Interventions
    Normal saline; Amphotericin B deoxycholate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-06-03
    Completion
    2026-08-31
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pulmonary Aspergillosis; CPA; Aspergilloma
    InterventionNormal saline; Amphotericin B deoxycholate
    PhasePhase 3
    Registry statusUnknown

  • Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas

    NCT07014163 · start 2024-05-21

    Registered record
    Registry ID
    NCT07014163
    Conditions
    Lipoma
    Interventions
    Embella (Deoxycholic acid, produced by Espad Pharmed Co.)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-05-21
    Completion
    2026-06-20
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLipoma
    InterventionEmbella (Deoxycholic acid, produced by Espad Pharmed Co.)
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

    NCT06132165 · start 2024-03-01

    Registered record
    Registry ID
    NCT06132165
    Conditions
    Neurofibromatosis 1
    Interventions
    Deoxycholic Acid; Polidocanol; 1064nm Nd:YAG laser; 755nm Alexandrite Laser
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-03-01
    Completion
    2025-07-31
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurofibromatosis 1
    InterventionDeoxycholic Acid; Polidocanol; 1064nm Nd:YAG laser; 755nm Alexandrite Laser
    PhasePhase 1
    Registry statusCompleted

  • Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus

    NCT05902468 · start 2023-06-28

    Registered record
    Registry ID
    NCT05902468
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Ursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2023-06-28
    Completion
    2024-11-28
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionUrsodeoxycholic acid
    PhasePhase 2 / Phase 3
    Registry statusUnknown